# The Confirmatory Olmesartan Plaque Regression Study

Study · id `cardio:ct-nct01132768` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01132768](<https://clinicaltrials.gov/study/NCT01132768>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01132768

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 114 participants.

## Technical summary

Registry record NCT01132768. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 114 participants (enrolled count; ClinicalTrials.gov record NCT01132768, source copy `cardio:ctgov-nct01132768-2018-12-24`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01132768, source copy `cardio:ctgov-nct01132768-2018-12-24`, retrieved 2026-10-26)
- Primary completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01132768, source copy `cardio:ctgov-nct01132768-2018-12-24`, retrieved 2026-10-26)
- Completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01132768, source copy `cardio:ctgov-nct01132768-2018-12-24`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01132768, source copy `cardio:ctgov-nct01132768-2018-12-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01132768-2018-12-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Confirmatory Olmesartan Plaque Regression Study
- Acronym: CONFIRM
- Condition: Essential Hypertension
- Condition: Carotid Plaque
- Intervention (Drug): Atenolol
- Intervention (Drug): olmesartan medoxomil
- Lead sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Atenolol (`cardio:atenolol`)
- Registry intervention name matches this record: Olmesartan (`cardio:olmesartan`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (`cardio:org-daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company`)

## Provenance

Content hash: 967e65d9bcdff5493f2b5ca646ba0f60b7592234b02eeb4b44883ea81cb03289
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
